Invivyd (NASDAQ:IVVD) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Invivyd (NASDAQ:IVVD) in a report released on Thursday,Benzinga reports. They currently have a $9.00 price target on the stock.

A number of other research firms have also recently commented on IVVD. Morgan Stanley reduced their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, HC Wainwright dropped their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $7.89.

Invivyd Stock Performance

Shares of NASDAQ:IVVD opened at $0.70 on Thursday. The business’s 50-day simple moving average is $0.97 and its 200 day simple moving average is $1.22. The company has a market cap of $83.90 million, a P/E ratio of -0.36 and a beta of 0.65. Invivyd has a one year low of $0.69 and a one year high of $5.20.

Hedge Funds Weigh In On Invivyd

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in shares of Invivyd during the 1st quarter worth approximately $56,000. Vanguard Group Inc. boosted its holdings in shares of Invivyd by 3.9% in the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock valued at $11,594,000 after acquiring an additional 97,496 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Invivyd by 21.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock valued at $1,933,000 after acquiring an additional 77,603 shares during the period. Tidal Investments LLC bought a new stake in Invivyd during the first quarter worth approximately $126,000. Finally, Bank of New York Mellon Corp bought a new position in Invivyd during the 2nd quarter valued at $263,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.